Oxurion NV
OXUR | BR
Overview
Corporate Details
- ISIN(s):
- BE0974487192
- LEI:
- 549300VWY8KVDFKLDM59
- Country:
- Belgium
- Address:
- Gaston Geenslaan 1, 3001 Heverlee
- Website:
- https://oxurion.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Oxurion is on a mission to transform the treatment of retinal disorders, including the development of THR-149, its novel therapeutic for the treatment of DME. Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Oxurion NV.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-07 18:00 |
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
|
English | 195.7 KB | |
| 2025-08-07 18:00 |
Regulatory News Service
FR_OXURION_PR_New-Development-Strategy_SD_20250806.pdf
|
French | 133.2 KB | |
| 2025-08-07 18:00 |
Earnings Release
OXUR-New-Development-Strategy-NL-20250806.pdf
|
Dutch | 213.8 KB | |
| 2025-08-07 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250807.pdf
|
English | 479.6 KB | |
| 2025-08-07 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250807.pdf
|
English | 506.8 KB | |
| 2025-08-04 08:30 |
M&A Activity
OXURION_PR_Closing_Acquisition_UK.pdf
|
English | 200.6 KB | |
| 2025-08-04 08:30 |
M&A Activity
OXURION_PR_Closing_Acquisition_FR.pdf
|
French | 157.5 KB | |
| 2025-08-04 08:30 |
M&A Activity
OXURION_PR_Closing_Acquisition_NL.pdf
|
Dutch | 246.7 KB | |
| 2025-07-30 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250723.pdf
|
English | 358.7 KB | |
| 2025-07-30 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250723.pdf
|
Dutch | 381.8 KB | |
| 2025-07-30 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250730.pdf
|
English | 360.1 KB | |
| 2025-07-30 18:00 |
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250730.pdf
|
Dutch | 383.3 KB | |
| 2025-07-30 18:00 |
Share Issue/Capital Change
OXUR-PR_Voting-rights-ENG_20250730.pdf
|
English | 281.6 KB | |
| 2025-07-30 18:00 |
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-NED_20250730.pdf
|
Dutch | 405.2 KB | |
| 2025-07-25 18:00 |
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-ENG_20250725.pdf
|
English | 281.3 KB |
Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oxurion NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-03-07 | Bareldam SA | Close relation | Buy | 1,180,555 | 1,700,000.00 EUR |
| 2021-09-30 | Lavinia D. Clay 2009 Revocable Trust | Close relation | Other | 2,766,337 | 5,601,002.52 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |